Thymidylate synthase (TS) is an essential enzyme that synthesizes thymidylic acid in the de novo biosynthetic pathway. Inhibiting TS enzyme activity with substrate or cofactor analogs leads to inhibition of DNA replication and cell death. For this reason, TS is an important target enzyme for cancer chemotherapeutic drugs. We describe an alternative approach to reducing cellular TS enzyme activity using short interfering RNA (siRNA) technology to lower TS mRNA levels. Plasmids that direct the synthesis of siRNAs that target nucleotides 898-916 and 965-983 (relative to the A of the translational start codon) of human TS mRNA were highly effective at reducing TS enzyme levels in transient transfection assays. Infection of HeLa cells with retroviruses that contain the effective siRNA genes led to a stable 80-95% reduction of TS enzyme and mRNA. A similar percent reduction in TS expression was observed in a cell line that overproduces TS enzyme 100-fold due to TS gene amplification. Cells that exhibited the greatest reduction in TS enzyme level grew poorly in medium that lacked thymidine. These observations suggest that siRNA approaches may provide an alternative therapeutic strategy to reduce TS enzyme levels.
Introduction
Thymidylate synthase (EC 2.1.1.45; TS) is the enzyme responsible for the synthesis of thymidine monophosphate (TMP) in the de novo biosynthetic pathway. TS catalyzes the reductive methylation of deoxyuridylic acid to form TMP using the cofactor N5,N10-methylenetetrahydrofolic acid as the methyl donor. 1 Cells can also synthesize TMP via the salvage pathway in which the enzyme thymidine kinase converts thymidine to TMP. However, in the absence of exogenous thymidine, cells depend exclusively on the de novo pathway for the synthesis of TMP. Owing to its role in the synthesis of a DNA precursor, TS is essential for the survival of proliferating cells, but not quiescent cells. For this reason, TS is an important target enzyme for a variety of cancer therapeutic drugs. Examples include substrate analogs such as 5-fluorodeoxyuridine and cofactor analogs such as raltitrexed. [2] [3] [4] These TS inhibitors have been successfully used, either alone or in combination with other drugs, to treat a variety of cancers.
Unfortunately, tumor cells develop resistance to TS inhibitors as a result of mutations that lead to changes in critical amino acids in the enzyme. 5 Cells also develop drug resistance via overproduction of TS. [6] [7] [8] TS overproduction can result from several different mechanisms. First, binding of inhibitors to TS leads to increased stability of the enzyme. 9 Second, the translation of TS mRNA is negatively autoregulated by the binding of TS enzyme to its mRNA. [10] [11] [12] This binding is disrupted when TS substrates or inhibitors are bound to the enzyme, leading to relief of translational repression and increased production of the enzyme. Finally, long-term exposure to TS inhibitors selects for cells in which TS is highly overproduced as a result of TS gene amplification. [13] [14] [15] The development of RNA interference technology has provided an alternative strategy to lower cellular TS enzyme activity by destroying the mRNA that encodes the enzyme. In mammalian cells, RNA interference involves the use of short interfering double-stranded RNA (siRNA) molecules that correspond to a specific mRNA that is targeted for destruction. 16, 17 The siRNA molecule associates with cellular proteins to form an RNA-induced silencing complex (RISC). The antisense strand of the siRNA directs the RISC complex to the targeted mRNA, which leads to endonucleolytic cleavage and subsequent destruction of the message. The technique has been widely used to inactivate the expression of specific genes in many eukaryotic organisms, and has the potential to be of great value in the treatment of viral infections, cancer and other diseases. [18] [19] [20] [21] Using the siRNA approach to inactivate TS gene expression should have the same outcome as using substrate or cofactor analogs to reduce TS enzyme activity, while reducing the problem of drug resistance following exposure of cells to TS enzyme inhibitors. Furthermore, stable introduction of a gene that encodes siRNA corresponding to TS mRNA could be used to permanently reduce the expression of the TS gene in targeted cells.
In this paper, we investigate the use of siRNA technology to bring about the stable inactivation of TS gene expression in cultured human cells. We first identified effective regions of TS mRNA for targeting by siRNA. We then developed a retroviral vector that carries a gene expressing the effective siRNA sequence. Infection of HeLa cells with the engineered retrovirus results in as much as a 95% reduction of TS enzyme and mRNA in cells that incorporated the retroviral genome, and led to a striking reduction in cell proliferation.
Materials and methods
Cell culture TS-deficient V79 Chinese hamster fibroblasts 22 were maintained in Dulbecco's modification of Eagle's medium (DMEM) supplemented with 10% NuSerum (BD Biosciences) and 10 mM thymidine. HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Hyclone). The Phoenix Ampho retroviral packaging cell line 23 was maintained in DMEM supplemented with 10% FBS. Hep-2/500 cells, in which the TS gene is amplified approximately 100-fold, 15 were maintained in DMEM containing 10% FBS.
Plasmid construction
The hTS expression plasmid that directs the synthesis of wild-type human TS was created by amplifying the fulllength human TS coding region by PCR using cDNA synthesized from HeLa total cellular RNA as the template, 5 0 ccacATGcctgtggccggctcg 3 0 as the forward primer and 5 0 tgccagtggcaacatccttaaaaatta 3 0 as the reverse primer. The amplified region starts at the AUG translational start codon and extends 157 nucleotides (nt) beyond the translational termination codon of the TS mRNA. The TS coding region was cloned into the mammalian expression plasmid pcDNA-DEST47 (Invitrogen). Transcription of the human TS coding region in this plasmid is driven by the cytomegalovirus promoter.
The pSHAG1 plasmid 24 for synthesizing siRNA and protocols for designing the inserts that encode siRNA were kindly provided by Greg Hannon (Cold Spring Harbor Laboratories). The siRNA gene inserts were cloned between the BseRI and BamHI sites of the pSHAG1 plasmid. pRS (pRETRO-SUPER) 18 plasmids were constructed by inserting the siRNA gene inserts between the BglII and HindIII sites of pRS. The siRNA gene inserts that were analyzed are described in Table 1 . The pRS plasmid containing both the TS898 and TS965 gatccccGGATATTGTCAGTCTTTAGttcaagagaCTAAAGACTGACAATATCCtttttggaaa gggCCTATAACAGTCAGAAATCaagttctctGATTTCTGACTGTTATAGGaaaaaccttttcga a Capital letters: sequences that participate in the formation of the double-stranded region of the RNA hairpin structure. #, first nucleotide of the mRNA sense sequence included in the siRNA gene insert. For the TS2 and TS889 inserts, several nucleotide changes were made in the sequence of the sense strand to allow the formation of GT base pairs in the hairpin structure. 24 Stable inhibition of TS expression by siRNA genes Z Yang et al siRNA genes was constructed in the following manner. The TS965 siRNA gene beginning from the H1 promoter and extending 60 nt beyond the HindIII site was PCR amplified using an upstream primer that included a HindIII site. The amplified region was digested with HindIII and cloned into the unique HindIII site downstream of the TS898 siRNA gene. Sequence analysis revealed that both siRNA genes were cloned in the same orientation.
Cotransfection analyses
For the cotransfection analyses, 2 Â 10 5 TS-deficient V79 cells were seeded on 35 mm dishes. After 6 h, the cells were transfected with 0.6 mg of the hTS plasmid, various amounts of the pSHAG or pRS plasmid containing an siRNA insert and sufficient pSHAG or pRS plasmid without insert to bring the total amount of transfected DNA to 1.2 mg in each sample. The DNA sample was transfected using Lipofectamine as the transfection reagent, as described by the manufacturer (Invitrogen). Cell extracts were prepared 2 days after transfection.
Analysis of TS enzyme and mRNA levels
The amount of TS enzyme was determined by measuring the formation of the covalent ternary complex between TS, [6-
0 -fluoro 2 0 -deoxyuridine 5 0 -monophosphate (10.7 Ci/mmol) (Moravek Biochemicals) and N5,N10-methylene-tetrahydrofolic acid (Sigma), as described previously. 13, 25 Trichloroacetic acid-insoluble material was collected by filtration through glass fiber filters and analyzed for radioactivity in a scintillation counter. In the indicated experiments, the amount of TS enzyme was normalized to the amount of total protein in the cell extract, which was determined by the DC Protein Assay (BioRad).
TS mRNA level was determined by real-time PCR. Briefly, total cellular RNA was isolated from cultured cells using the absolutely RNA RT-PCR miniprep kit (Stratagene). cDNA was made using the SuperScript firststrand synthesis system (Invitrogen). An oligo(dT) primer and 0.1 mg of total RNA were used in each 20 ml cDNA reaction. Control reactions were carried out under identical conditions, except for the omission of reverse transcriptase. Real-time PCR was performed in 96-well plates using the BioRad iCycler iQ Real-Time Detection System. Each 25 ml real-time PCR reaction consisted of a 1-ml sample of the cDNA preparation, 12.5 ml of iQ SYBR Green Supermix (BioRad), 1 ml of primer mix (containing 10 mM of each primer) and 10.5 ml water. Each cDNA preparation was analyzed in triplicate. The cycling parameters were 3 min at 941C (initial incubation), followed by 45 cycles of 15 s at 941C, 30 s at 621C and 30 s at 721C. The TS forward primer was 5 0 attcagctt cagcgagaacc 3 0 . The primer spanned exons 6 and 7 to ensure that the amplified products correspond to spliced RNA. The TS reverse primer (in exon 7) was 5 0 gatgcggattgtacccttca 3 0 . The TS PCR product was 115 nt in length. For normalization purposes, ribosomal protein L4 (rpL4) mRNA was also measured. The rpL4 forward primer (spanning exons 2 and 3) was 5 0 cttttggaaa catgtgtcgtgg 3 0 and the reverse primer (in exon 3) was 5 0 ctttagacatgaccagtgctgg 3 0 . The rpL4 PCR product was 150 nt in length. The efficiencies of each primer pair were calculated by generating a standard curve, and were 102% for TS mRNA and 92% for rpL4 mRNA. Real-time PCR data were analyzed using the comparative C T method. 26, 27 The amount of TS mRNA was normalized to the amount of control rpL4 mRNA to determine the relative amount of TS mRNA in each sample. Analyses of the control reactions (omitting reverse transcriptase) showed no detectable PCR signal, indicating that the signals in the experimental samples were not derived from contaminating DNA.
Retroviral infection
Phoenix-Ampho cells were plated in DMEM (without antibiotics) supplemented with 10% FBS and 10 mM thymidine at a density of 0.8 Â 10 6 in 60-mm culture dishes coated with poly-D-lysine to facilitate cell adherence. The next day, the medium was replaced with 3 ml of fresh medium, and the cells were transfected with 5 mg of the pRS-TS898 using Lipofectamine 2000 as the transfection reagent, as described by the manufacturer (Invitrogen). Cells were incubated at 371C in 5% CO 2 . The following day, the medium was replaced with 3 ml of DMEM supplemented with 10% FBS and 10 mM thymidine. At 48 h after transfection, the first infection was performed. The medium from the Phoenix-Ampho cells was collected and transferred to a 15-ml centrifuge tube. The medium was centrifuged at 500 g for 5 min at 41C. The supernatant was transferred to a new tube, and fresh medium with 10 mM thymidine was added to bring the total volume to 3 ml. Polybrene was added to a final concentration of 4 mg/ml, and the mixture was added to HeLa cells that were seeded 16-24 h previously at a density of 3 Â 10 4 cells per 60 mm dish. After a 5 h incubation, 3 ml of medium was added to each plate. The infection procedure was repeated two additional times at 12-hour intervals. At 2 days after the third infection, the cells were treated with DMEM containing 10% FBS, 10 mM thymidine and 1 mg/ml puromycin (to select for cells that had integrated the retroviral genome) and maintained in this medium thereafter. Between 70-90% of the cells exposed to the retrovirus were resistant to puromycin, indicating a relatively high efficiency of infection and integration of the viral genome. In contrast, 100% of control (uninfected) HeLa cells were killed by the drug. Cells were harvested 4-6 days after puromycin addition and assayed for TS enzyme or mRNA level.
Proliferation of retroviral infected cells
HeLa cells infected with control or siRNA-expressing retroviruses were cultured in DMEM supplemented with 10% FBS and 1 mg/ml puromycin at an initial density of 0.8 Â 10 4 cells per 35 mm culture dish. Control cultures were plated in the same medium supplemented with 10 mM thymidine. The medium was changed every 4 days. Duplicate cultures were harvested every 48 h, and total protein per dish was determined using the DC Protein Assay (BioRad).
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Results

Identification of an effective siRNA target sequence
Since there is considerable variability in the effectiveness of different siRNA sequences, our first objective was to identify a region of human TS mRNA that could be targeted for destruction by siRNA. Since our ultimate goal was to introduce an siRNA gene that would permanently reduce TS expression, our strategy was to transfect plasmids that contain siRNA genes rather than directly transfect siRNA into cultured cells. The plasmids contain an RNA polymerase III promoter that directs the synthesis of small RNA molecules that form hairpin structures (shRNA). 24 The double-stranded regions of the hairpins correspond to various regions of TS mRNA. The shRNA is processed by an RNase III enzyme (Dicer) to yield an siRNA molecule that associates with the RISC complex and directs the endonucleolytic cleavage of the human TS mRNA. 16, 17 The effectiveness of the siRNA gene inserts was measured by cotransfecting the plasmids encoding the siRNAs along with a plasmid that directs the synthesis of human TS into a TS-deficient hamster V79 cell line, and measuring TS enzyme level 2 days later. Two different siRNA expression plasmids were used in these analyses. Our initial studies were performed with pSHAG, 24 which uses the U6 promoter to transcribe the inserted siRNA gene. Subsequent analyses were performed with pRS, 18 which uses the H1 promoter to transcribe the inserted siRNA gene. The pRS plasmid also contains sequences that can be used to package the siRNA gene into retroviruses (see below). Transcription is terminated in both plasmids by a short stretch of T residues following the siRNA gene. The DNA sequences that were cloned into the plasmids are shown in Table 1 .
The results of the cotransfection assays using the pSHAG plasmid are summarized in Figure 1a . The control pSHAG-Luc plasmid, which targets luciferase mRNA, had little effect on TS expression, as expected. The pSHAG-TS2 plasmid, which synthesizes siRNA targeting 2-29 nt of the TS coding region, also had little effect on TS enzyme expression. However, pSHAG-TS889, which targets 889-916 nt, inhibited TS expression by approximately 98%. To determine the dose-response profile for the pSHAG-TS889 plasmid, increasing amounts of the pSHAG-TS889 plasmid were cotransfected with a constant amount of the human TS expression plasmid, and the amount of TS enzyme was determined. Figure 1b shows that the inhibition of TS enzyme production ranged from 50% with 0.01 mg of the pSHAG-TS889 plasmid to 98% with 0.6 mg of the plasmid.
To test the specificity of the pSHAG-TS889, we performed the cotransfection experiment using a mouse TS expression plasmid in place of the human TS expression plasmid. The mouse and human mRNA sequences targeted by the pSHAG-TS889 plasmid differ at two positions. Figure 1a shows that the pSHAG-TS889 plasmid was able to inhibit mouse TS enzyme expression by 82%. Surprisingly, the TS889 sequence was far less effective when cloned into the pRS plasmid (not shown), suggesting that the promoter or other surrounding sequences may influence the effectiveness of the siRNA sequences. However, we found that pRS-TS898, which targets a similar region of TS mRNA (898-916 nt), was able to inactivate TS expression by approximately 90% in the cotransfection assay (Figure 2) . We also tested pRS-TS115, which targets the sequence between 115 and 133 of the TS coding region. The pRS-TS115 plasmid had little effect on TS gene expression. Table 1 . At 2 days after transfection, cells were harvested and TS enzyme level was determined as described in Materials and methods. The values were normalized to the value observed in the absence of TS siRNA gene and plotted as a percentage to facilitate comparisons. Each bar represents the average of two independent experiments that differed from the mean by less than 15%. (b) TS-deficient hamster V79 cells were cotransfected with 0.6 mg of pHTS and the indicated amounts (in mg) of pSHAG-TS889 (TS889) or pSHAG lacking an siRNA gene insert (no ins.). TS enzyme level was determined 2 days later. Each bar represents the average of two independent experiments that differed from the mean by less than 15%.
Stable inactivation of endogenous TS expression following retroviral insertion of an siRNA gene
The above analyses identified an effective siRNA target sequence near the 3 0 end of the coding region of human TS mRNA. Our next goal was to develop a retroviral delivery vector for the TS898 siRNA gene. This would permit the efficient and stable incorporation of the siRNA expression cassette into the genome of cells infected with the virus, leading to a permanent reduction in TS gene expression. The pRS plasmid used in the cotransfection analyses includes sequences that are required for retroviral packaging of the RNA encoded by the plasmid as well as a gene conferring resistance to puromycin. 18 To package the TS siRNA gene into a retrovirus, the pRS-TS898 plasmid was transiently transfected into the Phoenix-Ampho cell line, an amphotropic retroviral packaging cell line that does not produce helper viruses. 23 Culture medium containing the retroviruses produced by the transfected cells was collected and added to cultured HeLa cells. The infected HeLa cells were grown in the presence of thymidine (which allows for the growth of TSdeficient cells) and puromycin (to select for cells that had integrated the retroviral genome). Nearly all of the cells that were exposed to the virus appear to have incorporated the retroviral genome, as judged by the fact that very few of the cells were killed by puromycin. In contrast, greater than 99% of control uninfected HeLa cells were killed by the drug. Figure 3a shows that, when HeLa cells were infected with the retrovirus that directed the expression of TS898 siRNA, TS enzyme level was reduced by approximately 80% (and in other experiments (Figure 4 ) up to 90%) relative to cells infected with the retrovirus that lacked the siRNA gene. We also measured the amount of TS mRNA in cells infected with the TS898 retrovirus and found that the mRNA was reduced to a similar extent (Figure 3b) .
To determine if integration of the TS898 retrovirus led to long-term inactivation of TS gene expression, the infected cells were grown for 1 month in the presence or absence of puromycin and again tested for TS enzyme and mRNA levels. Figure 4 shows that TS enzyme level was reduced approximately 85% after growth for 1 month in either the presence or absence of puromycin selection, indicating that the siRNA gene inserted by the TS898 retrovirus was stably maintained and expressed for at least this interval.
The residual TS enzyme observed in the cells infected with the retrovirus could be due to the fact that the TS siRNA gene was expressed at a level insufficient to inactivate all of the TS mRNA that was present in HeLa cells. To test this possibility, we repeated the retroviral infection experiment using Hep2-500 cells instead of HeLa cells. Hep2-500 cells are a fluorodeoxyuridineresistant derivative of human laryngeal carcinoma Hep2 cells that overproduce TS, and its mRNA approximately 100-fold due to amplification of the TS gene. 15 Integration of the retroviral siRNA gene brought about an 80% reduction in TS enzyme level in the Hep2-500 cells (not shown) even though the amounts of TS enzyme and mRNA are about 100 times greater in Hep2-500 cells than in HeLa cells. Therefore, the inability of the siRNA to completely inactivate TS expression in HeLa cells does not appear to be the result of insufficient siRNA production. Figure 2 Inhibition of TS expression in transient cotransfection assays using the pRS plasmid. The experiment was performed as described in Figure 1a , except that pRS plasmids containing the indicated siRNA gene inserts were used instead of the pSHAG plasmids. Figure 3 Retroviral delivery of the TS siRNA gene. HeLa cells were infected with retroviruses containing the indicated siRNA gene or with control retroviruses lacking the siRNA gene insert (pRS). Cultures were assayed for TS enzyme level (a) or TS mRNA level (b) as described in Materials and methods. TS enzyme levels were normalized to the amount of total protein in the cell extract, and TS mRNA levels were normalized to the level of rpL4 mRNA, to correct for differences in cell number in the different cultures. These values were then normalized to the value observed for cells infected with retroviruses that lacked an siRNA gene to facilitate comparisons.
Stable inhibition of TS expression by siRNA genes Z Yang et al Although the TS898 retrovirus was able to stably reduce TS expression by 80-90%, this level of inhibition was unlikely to be therapeutically effective. Previous studies using TS enzyme inhibitors 28 indicated that greater than 95% inhibition of TS activity was necessary to observe a significant effect on cell proliferation. Recently, Schmitz et al. 29 identified another TS mRNA sequence downstream of the translational termination codon (965-983 nt relative to the A of the translational start codon) that can be effectively targeted by siRNA. To determine if this sequence was more effective than the TS898 sequence, we inserted a gene encoding the alternative siRNA sequence (Table 1) into the pRS plasmid to form pRS-TS965. Figure 2 shows that the pRS-TS965 plasmid was 2-3 times more effective than the pRS-TS898 plasmid in transient cotransfection assays, indicating that the 965-983 sequence was a highly effective target. We also constructed a pRS plasmid that contained both the TS965 siRNA gene and the TS898 siRNA gene (each driven by its own H1 promoter). The different pRS plasmids were used to produce retroviruses that encoded the TS siRNA genes, as described above. Figure 3 shows that, when HeLa cells were infected with the TS965 retrovirus, TS enzyme and mRNA levels were reduced 90-95% relative to cells infected with the retrovirus without siRNA gene. TS enzyme level was consistently 2-3 times lower in cells infected with the TS965 retrovirus than in cells infected with the TS898 retrovirus. Surprisingly, the retrovirus that contained the TS965 as well as the TS898 siRNA genes was somewhat less effective than the retrovirus that contained only the TS965 siRNA gene.
To determine the effects of the TS siRNA sequences on cell proliferation, cultures of HeLa cells infected with the retroviruses were seeded in medium containing or lacking thymidine, and the amount of cellular protein was determined at subsequent times. HeLa cells infected with the retrovirus that lacked an siRNA gene (Figure 5a ) or with a retrovirus containing the TS898 siRNA gene (Figure 5b) grew at approximately the same rate in the presence or absence of thymidine. This confirms that the 80-90% reduction in TS enzyme level brought about by the TS898 retrovirus was insufficient to affect cell proliferation. However, HeLa cells infected with the TS965 retrovirus grew well in the presence of thymidine, Figure 4 Retroviral delivery of the TS898 siRNA gene leads to long-term reduction of TS enzyme levels. HeLa cells were infected with retroviruses containing the TS898 siRNA gene (TS898) or with control retroviruses lacking the siRNA gene insert (no ins.). Control cultures (Uninf.) were not exposed to the virus. Some of the cultures were harvested 1 week after infection and assayed for TS enzyme level. Other cultures were grown for an additional month in medium containing thymidine and puromycin (TS898 þ puro 1 mo) or thymidine but no puromycin (TS898 -puro 1 mo) before harvest. TS enzyme levels were normalized to the amount of total protein in the cell extract to correct for differences in cell number in the different cultures. These values were then normalized to the value observed for cells infected with retroviruses that lacked an siRNA insert to facilitate comparisons. Each bar represents the average of at least two determinations that differed from the mean by less than 15% for the virus-infected cells. (Figure 5c ), indicating that TS expression was reduced sufficiently in these cells to block cell proliferation.
Discussion
In the present study, we describe the application of siRNA technology to bring about a stable reduction of TS gene expression in cultured human cells. To accomplish this, it was necessary to integrate a gene that directed the synthesis of siRNA rather than simply transfecting siRNA itself since the latter approach would lead to a temporary rather than a long-term reduction in TS expression. We first identified highly effective siRNA target sequences near the 3 0 end of the coding region of TS mRNA. Plasmids that direct the synthesis of siRNA targeting these sequences inhibited TS expression up to 97% in transient transfection assays.
To bring about a permanent reduction in TS gene expression, the genes encoding the functional siRNA molecules were incorporated into a retroviral vector. Infection of HeLa cells with the engineered retroviruses led to an 80-95% reduction in TS enzyme level in cells that had incorporated the retroviral genome. The reduction in TS expression was maintained for at least 1 month in the absence of selection, indicating that the siRNA genes were maintained and expressed in the host cells for at least this interval. The reduction in TS enzyme level brought about by the TS898 retrovirus was not sufficient to prevent cell proliferation. This indicates that TS enzyme must be present in at least a 5-10-fold excess in HeLa cells. However, infection of cells with the TS965 retrovirus, which targeted a sequence in the 3 0 untranslated region of TS mRNA, led to significantly greater inhibition of TS expression than the TS898 retrovirus, as well as a striking reduction in cell proliferation.
The residual TS expression in the infected cells does not appear to be the result of inadequate expression of the siRNA gene. This was clearly demonstrated by the observation that retroviral insertion of the TS898 siRNA gene into a cell line that overproduced TS enzyme and mRNA approximately 100-fold due to TS gene amplification also led to an 80% reduction in TS expression. Therefore, a vast excess of siRNA appears to be produced in the infected cells. It is possible that the residual TS expression is due to the fact that recognition of the TS898 target sequence by the RISC complex is partially blocked by mRNA secondary structure, by proteins that interact with the mRNA in the vicinity of the target sequence or by ribosomes that are translating the mRNA.
Retroviral insertion of the TS965 sequence into HeLa cells led to a striking inhibition of cell proliferation (Figure 5c ). In contrast, Schmitz et al. 29 observed only a minor (25-30%) inhibition of proliferation when RKO human colon cancer cells were transiently transfected with siRNA corresponding to the same sequence targeted by the TS965 retrovirus. This might indicate that delivery of the siRNA was more effective in cells stably expressing a gene encoding the siRNA than in cells transiently transfected with the siRNA. However, the difference could also be the result of differences in sensitivity to TS inhibition between HeLa and RKO cells.
The use of siRNA may prove to be a highly effective alternative therapeutic strategy for reducing TS enzyme activity and treating cancer. The siRNA approach has several advantages over the use of chemotherapeutic drugs to reduce TS enzyme activity. For example, the siRNA approach avoids the potential problem of TS overproduction due to drug-induced disruption of TS translational autoregulation 10, 29 or enzyme stabilization, 9 since the mRNA itself is destroyed. Furthermore, singlepoint mutations in the siRNA target sequence are not likely to protect the TS mRNA from destruction (Figure 1a) , although minor sequence changes can lead to significant levels of resistance to chemotherapeutic drugs. 5 Finally, retroviral insertion of the TS siRNA gene leads to the permanent reduction in TS enzyme level without the need for continuous exposure to chemotherapeutic drugs. If retroviral vectors carrying the TS siRNA gene can be targeted specifically to tumor cells, this would also reduce the toxic effects of TS inhibition on normal proliferating cells.
Our results show that nearly complete inhibition of TS expression via siRNA is required to block cell proliferation in the absence of thymidine. However, Schmitz et al. 29 showed that a partial siRNA-mediated reduction of TS expression led to increased sensitivity of the cells to drugs that target the enzyme. Koehler and Ladner 30 recently showed that an siRNA-mediated decrease in dUTPase expression led to a substantial expansion of the cellular dUTP pool, as well as increased sensitivity of the cells to TS enzyme inhibitors. The increase in the ratio of dUTP/TTP under these conditions results in increased mis-incorporation of dUMP into DNA (in place of TMP) and enhanced DNA fragmentation due to base excision repair. These observations suggest that simultaneous siRNA targeting of both TS and dUTPase gene expression may have a synergistic effect, leading to a substantial increase in cytotoxicity.
A recent study has shown that forced overexpression of TS resulting from transfection of genes encoding human TS into cultured cells leads to neoplastic transformation of the transfected cells, 31 suggesting that the TS gene is also an oncogene. Mutations that block TS enzymatic activity prevent neoplastic transformation, indicating a correlation between catalytic and oncogenic activities of the enzyme. However, alternative explanations have also been proposed. 32 Regardless of the mechanism, it should also be possible to eliminate the oncogenic potential of TS by reducing (although not eliminating) the cellular level of TS via siRNA.
Clearly, there are many hurdles to overcome before siRNA technology can be applied in a variety of clinical situations. However, the power and simplicity of the approach are likely to provide alternative therapeutic strategies that result in greater success in treating cancer and other genetic diseases as well as viral infections.
